About this item:

165 Views | 152 Downloads



  • Science & Technology
  • Life Sciences & Biomedicine
  • Virology

CD40L adjuvant for DNA/MVA vaccine: enhanced protection from acquisition of neutralization sensitive & neutralization resistant mucosal SIV infections

Show all authors Show less authors


Conference Name:

AIDS Vaccine 2012, Boston, MA, USA. 9-12

Publication Date:

Type of Work:



Generating highly functional antibodies against HIV-1 is critical to prevent infection. Here we evaluated the ability of CD40L (a co-stimulatory molecule for B cells and dendritic cells) as an adjuvant to prevent mucosal infection from neutralization-susceptible (SIVE660) and neutralization-resistant (SIV251) SIVs.

Copyright information:

©2012 Kwa et al; licensee BioMed Central Ltd.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 2.0 Generic License (http://creativecommons.org/licenses/by/2.0/).

Creative Commons License

Export to EndNote